[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Gómez Portilla A, Cendoya I, Muriel J, Olabarria I, Guede N, Moraza N, Fernández E, Martínez de Lecea C, Magrach L, Martín E, Romero E, Aguado I, Valdovinos M, Larrabide I: [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]. Cir Esp; 2007 Feb;81(2):82-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
  • [Transliterated title] Mesotelioma peritoneal maligno. Nuestra experiencia con la triple terapia combinada: citorreducción, quimioterapia intraperitoneal perioperatoria e hipertermia.
  • INTRODUCTION: Malignant peritoneal mesothelioma is the most common primary neoplasm of the serous peritoneum.
  • Prognosis with traditional therapeutic options is dismal, with a median survival of between 4 and 12 months from diagnosis.
  • The application of a new combined therapy with cytoreductive surgery, intraperitoneal perioperative chemotherapy and heated intraperitoneal intraoperative chemotherapy, followed by early postoperative intraperitoneal chemotherapy is currently providing good results, in some instances even allowing curative intent.
  • We present a series of patients treated with this triple combined therapy.
  • Among these patients, surgery was performed on 11 occasions in seven patients with a diffuse malignant peritoneal mesothelioma.
  • RESULTS: Eleven cytoreductions were performed in seven patients with diffuse malignant peritoneal mesothelioma.
  • There were four men and three women, with a mean age of 50 years (range 31-57 years).
  • Only two patients had also received systemic chemotherapy as adjuvant treatment after their initial diagnosis, as the only possible therapeutic alternative.
  • Treatment with curative intent was provided, obtaining complete cytoreduction of macroscopic disease in all patients, followed by application of intraperitoneal perioperative chemotherapy for the treatment of any residual microscopic disease.
  • Pathologic analysis showed biphasic sarcomatous mesothelioma in two patients and epithelial mesothelioma in the remaining five patients.
  • Three patients died from disease progression at 3, 9 and 11 months after the initial cytoreduction; of these, two patients had diffuse biphasic sarcomatous mesothelioma.
  • The remaining four patients are still alive at 5, 9, 19 and 54 months after the initial cytoreduction without evidence of disease at the present time.
  • CONCLUSIONS: Radical oncologic cytoreductive surgery combined with intraperitoneal perioperative chemotherapy provides good results with prolonged survival in selected cases, although morbidity is high.
  • Based in our experience, biphasic sarcomatous mesotheliomas should be excluded from this protocol because of their aggressiveness; these tumors should be included only in conventional therapeutic strategies with palliative intent.
  • [MeSH-major] Mesothelioma / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Male. Middle Aged

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306123.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res; 2009 Apr 15;15(8):2818-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
  • PURPOSE: Present chemotherapeutic regimens are marginally efficient in tumor cells being particularly resistant to radiotherapy and/or chemotherapy.
  • We hypothesized that unresponsiveness of tumors to conventional therapeutic agents might be due to inappropriate gene expression resulting from epigenetic modifications and leading to transcriptional silencing.
  • The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor.
  • EXPERIMENTAL DESIGN AND RESULTS: We show that valproate augments apoptosis induced by pemetrexed and cisplatin in mesothelioma cell lines and in tumor cells from patient's biopsies.
  • Finally, valproate when combined with pemetrexed and cisplatin prevents tumor growth in mouse models of epithelioid mesothelioma.
  • CONCLUSIONS: These observations support the potential additional efficacy of valproate in combination with pemetrexed and cisplatin for treatment of malignant mesothelioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Enzyme Inhibitors / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Valproic Acid / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols. Apoptosis / drug effects. Apoptosis / physiology. BH3 Interacting Domain Death Agonist Protein / drug effects. BH3 Interacting Domain Death Agonist Protein / metabolism. Caspase 8 / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. Cyclin-Dependent Kinase Inhibitor p21 / agonists. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cytochromes c / drug effects. Cytochromes c / metabolism. Drug Synergism. Histones / drug effects. Histones / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, SCID. Mitochondria / drug effects. Mitochondria / metabolism. Pemetrexed. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351772.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Enzyme Inhibitors; 0 / Glutamates; 0 / Histones; 0 / Reactive Oxygen Species; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 614OI1Z5WI / Valproic Acid; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 8; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res; 2001 Feb;7(2):231-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro chemosensitivity of cancer cells to ET-743 is markedly enhanced by prolonging the duration of exposure to the drug.
  • (d) Eastern Cooperative Oncology Group performance status < or = 1, 20 patients; and (e) two prior regimens of chemotherapy, 7 patients.
  • Reversible grade 4 transaminitis occurred in two of nine patients after treatment with the first cycle of therapy at the third dose level of 1200 microg/m2.
  • Another patient experienced grade 4 rhabdomyolysis, renal failure requiring hemodialysis, grade 4 neutropenia, and grade 3 thrombocytopenia during the second cycle of therapy with this dose.
  • Toxicity of the drug is clearly schedule-dependent, because increasing the duration of infusion from 3 or 24 h to 72 h results in decreased myelosuppression and comparable hepatotoxicity.
  • Although there were no objective responses to therapy, clear evidence of antitumor activity was observed in a patient with epithelioid mesothelioma, as confirmed by positron emission tomography studies.
  • The therapeutically optimal administration schedule remains to be established, inasmuch as there have been indications of activity against a variety of tumors during Phase I studies when the drug was infused over times ranging from 1 to 72 h.
  • Characterizing the pharmacokinetics of ET-743 during the course of Phase II trials and Phase I combination studies is recommended to assure that this promising new anticancer drug can be used with an acceptable margin of safety.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine Transaminase / metabolism. Area Under Curve. Aspartate Aminotransferases / metabolism. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged. Models, Chemical. Tetrahydroisoquinolines. Time Factors. Toxicity Tests

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11234874.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


Advertisement
4. Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlöf AK, Fernandes AP, Björnstedt M, Dobra K: Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res; 2009;28:92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.
  • BACKGROUND: Selenite is a promising anticancer agent which has been shown to induce apoptosis in malignant mesothelioma cells in a phenotype-dependent manner, where cells of the chemoresistant sarcomatoid phenotype are more sensitive.
  • METHODS: In this paper, we investigate the apoptosis signalling mechanisms in sarcomatoid and epithelioid mesothelioma cells after selenite treatment.
  • Bax was up-regulated only in the sarcomatoid cell line, while the epithelioid cell line down-regulated Bcl-XL and showed greater caspase-3 activation.
  • Chemical inhibition of p53 did not protect the cells from apoptosis. p53 lost its DNA binding ability after selenite treatment and was enriched in an inactive form.
  • Levels of thioredoxin decreased after selenite treatment.
  • CONCLUSION: We delineate pathways of apoptosis signalling in response to selenite, showing differences between epithelioid and sarcomatoid mesothelioma cells.
  • [MeSH-major] Apoptosis / drug effects. Mesothelioma / drug therapy. Mesothelioma / pathology. Signal Transduction / drug effects. Sodium Selenite / pharmacology
  • [MeSH-minor] Caspase 3 / metabolism. Cell Proliferation. Flow Cytometry. Humans. Immunoenzyme Techniques. Luciferases / metabolism. Membrane Potential, Mitochondrial / drug effects. Phenotype. Proto-Oncogene Proteins c-bcl-2 / metabolism. Thioredoxins. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37474-80 [10982790.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] Differentiation. 2000 Dec;66(4-5):181-8 [11269944.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30542-51 [11375392.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):1017-24 [12082024.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):253-9 [12201488.001]
  • [Cites] Carcinogenesis. 2002 Oct;23(10):1609-15 [12376468.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1059-66 [12481429.001]
  • [Cites] Antioxid Redox Signal. 2003 Jun;5(3):273-9 [12880482.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12):2301-11 [14637188.001]
  • [Cites] Biochem Pharmacol. 2004 Feb 1;67(3):513-22 [15037203.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):354-62 [15172356.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):877-84 [15252149.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S103-19 [15261443.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4407-12 [8813134.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3633-8 [9108029.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] Mol Carcinog. 1998 Mar;21(3):205-14 [9537652.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):280-9 [9925742.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):820-8 [10328239.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3175-9 [10397262.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Histochem Cytochem. 2005 Feb;53(2):141-53 [15684327.001]
  • [Cites] Biochem Cell Biol. 2005 Apr;83(2):196-211 [15864328.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1827-40 [15920167.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3853-63 [15824742.001]
  • [Cites] J Pathol. 2005 Sep;207(1):91-101 [16007577.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1618-22 [16118627.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):218-25 [16173037.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2296-304 [16489034.001]
  • [Cites] Apoptosis. 2006 Feb;11(2):143-9 [16502253.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1873-82 [16891474.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):2078-85 [16928829.001]
  • [Cites] Free Radic Biol Med. 2006 Sep 15;41(6):874-85 [16934670.001]
  • [Cites] Differentiation. 2007 Feb;75(2):123-32 [17316382.001]
  • [Cites] J Pathol. 2007 Mar;211(4):447-54 [17253596.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):145-50 [17346688.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):591-601 [17409924.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):986-94 [17350081.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6314-24 [17616690.001]
  • [Cites] Cell Biol Toxicol. 2008 Apr;24(2):123-41 [17610029.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] Connect Tissue Res. 2008;49(3):270-2 [18661358.001]
  • [Cites] BMB Rep. 2008 Oct 31;41(10):745-50 [18959823.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jan;63(2):351-62 [18379781.001]
  • [Cites] Cell Physiol Biochem. 2008;22(5-6):387-94 [19088420.001]
  • [Cites] Biol Trace Elem Res. 2009 Mar;127(3):200-10 [18953506.001]
  • [Cites] Biochem Pharmacol. 1993 Jan 26;45(2):429-37 [8382065.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4469-73 [8402615.001]
  • [Cites] Biochem Pharmacol. 1995 Jul 17;50(2):213-9 [7632165.001]
  • [Cites] Nutr Cancer. 2009;61(2):251-64 [19235042.001]
  • [Cites] Nutr Cancer. 2009;61(3):397-407 [19373614.001]
  • [Cites] Free Radic Biol Med. 2009 Apr 15;46(8):1186-96 [19439215.001]
  • [Cites] Ann Hematol. 2009 Aug;88(8):733-42 [19153735.001]
  • [Cites] Cancer Lett. 2009 Sep 8;282(1):116-23 [19345479.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6118-22 [2790824.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35809-15 [10585464.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3508-15 [10589765.001]
  • [Cites] Free Radic Biol Med. 2001 Jan 1;30(1):9-21 [11134891.001]
  • (PMID = 19563663.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 52500-60-4 / Thioredoxins; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3; HIW548RQ3W / Sodium Selenite
  • [Other-IDs] NLM/ PMC2711967
  •  go-up   go-down


5. Tsai LY, Yang YL, Lu MY, Lin DT, Huang HY, Lin KH: Deciduoid mesothelioma of the pleura in an adolescent boy. Pediatr Hematol Oncol; 2010 Mar;27(2):132-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deciduoid mesothelioma of the pleura in an adolescent boy.
  • Deciduoid mesothelioma is an extremely rare variant of malignant epithelioid mesothelioma.
  • This report presents the case of a 13-year-old boy with this type of tumor in his pleura, whose initial main symptoms were chest pains and progressive scoliosis.
  • Ensuing chemotherapy, which comprised pemetrexed and cisplatin, yielded good response after 5 cycles.
  • Subsequent radical surgery was carried out and another 3 cycles of chemotherapy were given.
  • The patient has been doing well 2 years after completion of this regime of treatment.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201694.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME: Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine. Oncology; 2007;73(5-6):426-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
  • We report the case of a 56-year-old patient with malignant pleural mesothelioma of epithelial type, who responded to second-line chemotherapy with lipoplatin plus gemcitabine.
  • Eighteen months later, he presented with pleural effusion of the left side and underwent first-line chemotherapy with cisplatin plus vinorelbine.
  • After 8 cycles, the patient presented renal toxicity limiting further cisplatinum chemotherapy and disease progression with peritoneal invasion of the tumor and ascites.
  • Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fatal Outcome. Humans. Male. Middle Aged. Palliative Care. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18523361.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H, Comin CE, Murer B, Cagle PT, Attanoos R, Gibbs AR, Galateau-Salle F, Popper HH: EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax; 2008 Apr;63(4):345-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related tumour difficult to detect early and treat effectively.
  • Asbestos causes genetic modifications and cell signalling events that favour the resistance of MPM to apoptosis and chemotherapy.
  • METHODS: 37 antibodies detecting proteins engaged in cell signalling pathways, enforcing proliferation, antiapoptosis, angiogenesis and other cellular activities were investigated by tissue microarray (TMA) technology.
  • CONCLUSION: We have demonstrated that small scale proteomics can be carried out by powerful linkage of TMA, immunohistochemistry and statistical methods to identify proteins which might be relevant targets for therapeutic intervention.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / pathology. Neoplasm Proteins / metabolism. Pleural Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086752.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


8. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Tanimura H, Tsubota YT: Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma. Hepatogastroenterology; 2004 Jul-Aug;51(58):1073-83
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma.
  • We report a case of malignant peritoneal mesothelioma in a 63-year-old man.
  • Right hemicolectomy, partial ileectomy, partial omentectomy, excision of the abdominal wall, and catheterization for intraperitoneal infusion chemotherapy were performed as surgery.
  • The final diagnosis was a diffuse malignant mesothelioma of the epithelial type.
  • Secondly, we reviewed major chemotherapy previously described for malignant mesothelioma.
  • The response rates with single agent chemotherapy, combination chemotherapy, intraperitoneal or intracavitary chemotherapy, continuous hyperthermic peritoneal perfusion chemotherapy, and immunochemotherapy were 150 of 1,146 cases (13.1%), 209 of 1,019 cases (20.5%), 63 of 133 cases (47.4%), 11 of 13 cases (84.6%), and 36 of 182 cases (19.8%), respectively.
  • Direct exposure of antitumor agent to the peritoneal surface is considered to be most effective against malignant peritoneal mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyaluronic Acid / blood. Mesothelioma / blood. Mesothelioma / drug therapy. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239250.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; 9004-61-9 / Hyaluronic Acid; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 173
  •  go-up   go-down


9. Small GR, Nicolson M, Buchan K, Broadhurst P: Pericardial malignant mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac Surg; 2008 Apr;33(4):745-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial malignant mesothelioma: a latent complication of radiotherapy?
  • Post-embolectomy she developed cardiac failure.
  • Adjuvant chemotherapy and radiotherapy were administered.
  • Histology revealed pericardial epithelioid malignant mesothelioma.
  • Chemotherapy with pemetrexed and carboplatin was given.
  • Radiotherapy and asbestos exposure are both associated with pericardial mesothelioma and the aetiology in this case was not clear.
  • The condition carries a poor prognosis and is invariable fatal although newer chemotherapeutic regimens have prolonged survival times.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Heart Neoplasms / etiology. Mesothelioma / etiology. Neoplasms, Radiation-Induced / etiology. Pericardium

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280176.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Kawamata O, Kondu Y, Murata T, Uetsuka H, Uda M, Nakai H, Ohta T: [Malignant pleural mesothelioma]. Kyobu Geka; 2007 Jan;60(1):31-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma].
  • Malignant pleural mesothelioma carries a poor prognosis, for which no standard therapy has been established.
  • We report 15 cases of malignant pleural mesothelioma experienced since 2000 focusing on their clinical features.
  • Histology of the pleural biopsy specimen showed epithelial mesothelioma in 8 patients, biphasic mesothelioma in 3, sarcomatous mesothelioma in 2 and desmoplastic malignant mesothelioma (DMM) in 2.
  • Twelve patients received chemotherapy.
  • In addition to 2 of these 3 patients, 2 underwent extrapleural pneumonectomy (EPP) without adjuvant treatment.
  • Remaining 1 received palliative treatment only.
  • The longest survival time with chemotherapy is 41 months in a surviving patient with epithelial mesothelioma and that with EPP is 25 months in a surviving patient with DMM.
  • The 2-year survival rate of the 14 patients was 44.4% and the median survival time in patients with epithelial mesothelioma was 30.6 months.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249535.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Markaki S, Protopapas A, Milingos S, Lazaris D, Antsaklis A, Michalas S: Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study. Gynecol Oncol; 2005 Mar;96(3):860-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study.
  • BACKGROUND: Primary peritoneal mesothelioma is regarded as a fatal disease that presents with progressive ascites at a relatively late stage of its natural history.
  • CASE: A 54-year-old woman presented to our institution with a 4-month history of dull epigastric pain and increased abdominal girth.
  • Exploratory laparotomy revealed the presence of extensive intraperitoneal dissemination of a malignant neoplasm without a recognizable primary site.
  • Suboptimal cytoreduction was carried out, and histological diagnosis was that of a malignant epithelioid mesothelioma.
  • This was confirmed with a panel of immunohistochemical markers.
  • The patient despite having a complete response after adjuvant chemotherapy died 18 months after primary surgery.
  • CONCLUSION: No single immunohistochemical stain is pathognomonic of peritoneal primary malignant mesothelioma (PMM), and the results of a panel of antibodies should be interpreted to set the diagnosis.
  • [MeSH-major] Mesothelioma / metabolism. Mesothelioma / pathology. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721439.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Singhal S, Kaiser LR: Malignant mesothelioma: options for management. Surg Clin North Am; 2002 Aug;82(4):797-831
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: options for management.
  • In the past, there has been a tendency to think of diffuse malignant pleural mesothelioma as one disease in therapeutic terms, regardless of histological type and tumor stage.
  • This does not happen with other tumors, yet it is equally illogical and inappropriate in mesothelioma.
  • As with other tumors, early diagnosis-while the disease is still in stage I, or even at an in situ stage-must be the goal so that therapy can be maximized, particularly if immunotherapy or gene therapy is to be used.
  • Patients with pure epithelial mesothelioma have a better prognosis and respond better to trimodality therapy.
  • Stage I patients who meet fitness criteria should be offered the option of radical surgery in combination with chemotherapy and radiotherapy.
  • Further research is required to determine the optimum neoadjuvant and adjuvant modalities, particularly the timing of individual drugs, use of hyperthermia, and route of administration.
  • The place of immunotherapy and gene therapy as adjunctive treatments also remains to be defined.
  • For example, it may be possible to reduce tumor bulk and perhaps downstage the disease with immunotherapy before radical surgery, if treatment is started early enough.
  • Gene therapy may have a role either preoperatively or in destroying the microscopic disease that remains after radical surgery.
  • These and other combinations of treatment need to be tested in well-designed clinical trials, probably on a multicenter basis (to enroll a sufficient number of patients).
  • Finding the means to improve treatment for sarcomatous and mixed histology mesothelioma remains a challenge.
  • At present, radical surgery does not seem worthwhile for these patients when combined with currently employed chemotherapy and radiotherapy; however, chemotherapy combinations used for treating other sarcomas need to be evaluated as adjunctive therapy before radical surgery is abandoned altogether as a mode of treatment.
  • A collaborative approach involving thoracic surgeons, basic scientists and oncologists, and physicians with experience in treating mesothelioma is essential.
  • Despite its increasing frequency, mesothelioma is still a relatively rare tumor, so treatment should be concentrated in relatively few supraregional centers to maximize expertise and allow innovative treatment combinations to be implemented with the greatest chance of success.
  • Evaluation of new therapeutic approaches will be achieved more rapidly if these supraregional centers collaborate in multicenter trials.
  • The nihilistic approach of simply waiting until the mesothelioma epidemic eventually begins to decline spontaneously in 20 or 30 years is untenable in view of the hundreds of thousands of deaths that will result if no effective treatment is found.
  • [MeSH-major] Lung Neoplasms / therapy. Mesothelioma / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12472131.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 189
  •  go-up   go-down


14. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, Zannini P: 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur J Cardiothorac Surg; 2000 Apr;17(4):377-83
Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
  • The CT scan, which is the current diagnostic technique, has limited accuracy both in the differentiation between benign and malignant pleural diseases and in the diagnosis of primary and metastatic pleural neoplasms.
  • The increasing incidence of malignant pleural mesothelioma has led to the development of new treatment strategies, which still need to be fully validated.
  • There is, therefore, a need for new diagnostic techniques that can lead to a definite diagnosis and a satisfactory evaluation of the response to treatment.
  • Encouraging results have been reported with the F-18-labeled analogue of 2-deoxyglucose (18-FDG) positron emission tomography (PET) in the evaluation of chest tumors such as lung cancer.
  • PET was also performed before and after treatment in patients who underwent chemotherapy to evaluate the accuracy of this technique in the assessment of the response.
  • Histology demonstrated a malignant pleural disease in 13 patients; malignant pleural mesothelioma in ten patients, adenocarcinoma in two and liposarcoma in one.
  • PET assessment demonstrated significant 18-FDG uptake in 12 of the 13 patients with a malignant disease, also revealing distant metastases in two of them.
  • A false-negative result was observed in a patient with an epithelial mesothelioma.
  • An aspecific uptake was observed in two patients who had undergone pleurectomy and intrapleural chemotherapy.
  • A decreased tracer uptake was observed after chemotherapy in four patients.
  • CONCLUSIONS: These preliminary results demonstrate that 18-FDG PET may have a great potential, both in the differential diagnosis of pleural diseases and in the evaluation of the response to treatment.
  • At present, however, histological thoracoscopic diagnosis remains mandatory before planning treatment.
  • [MeSH-major] Deoxyglucose / analogs & derivatives. Image Enhancement. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Evaluation Studies as Topic. Female. Follow-Up Studies. Humans. Liposarcoma / drug therapy. Liposarcoma / pathology. Liposarcoma / radionuclide imaging. Male. Mesothelioma / drug therapy. Mesothelioma / pathology. Mesothelioma / radionuclide imaging. Middle Aged. Pilot Projects. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10773558.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


15. Butnor KJ, Sporn TA, Hammar SP, Roggli VL: Well-differentiated papillary mesothelioma. Am J Surg Pathol; 2001 Oct;25(10):1304-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma.
  • Well-differentiated papillary mesothelioma is an unusual variant of epithelial mesothelioma considered to be of low malignant potential.
  • The majority of previously reported cases developed in the peritoneum of young women without a history of asbestos exposure.
  • The authors report 14 cases of well-differentiated papillary mesothelioma, seven of which originated in the pleura, six in the peritoneum, and one in the tunica vaginalis.
  • Of the nine cases with complete follow-up, six had clinically indolent disease, one showed resolution after adjuvant chemotherapy, one pursued an aggressive course, and one died of other causes.
  • These findings indicate that well-differentiated papillary mesothelioma is a rare variant of mesothelioma with a variable clinical prognosis that is etiologically related to asbestos exposure in some cases.
  • [MeSH-major] Mesothelioma / pathology. Peritoneal Neoplasms / pathology. Pleural Neoplasms / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11688466.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  •  go-up   go-down


16. Khalil LY, Szturmowicz M, Wawrzyńska L, Fijałkowska A, Kupis W, Maszkowska-Kopij K, Szczepulska E, Burakowska B, Tomkowski W, Torbicki A: [Diagnostic difficulties in primary mesothelioma]. Pneumonol Alergol Pol; 2004;72(5-6):221-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in primary mesothelioma].
  • A 54-year-old woman with a history of fatigue and shortness of breath was found to have a pericardial effusion and mild mediastinal lymphadenopathy.
  • Following 5 courses of chemotherapy--given over a 4 month period--the amount of pericardial effusion and pericardial thickness did not change.
  • The final diagnosis was primary pericardial mesothelioma of epithelioid type.
  • The case illustrates the difficulties in establishing diagnosis of primary pericardial mesothelioma which is a rare tumor with poor prognosis.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757264.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Zanconati F, DelConte A, Bonifacio-Gori D, Falconieri G: Metastatic pleural mesothelioma presenting with solitary involvement of the tongue: report of a new case and review of the literature. Int J Surg Pathol; 2003 Jan;11(1):51-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pleural mesothelioma presenting with solitary involvement of the tongue: report of a new case and review of the literature.
  • We report a new case of mesothelioma that presented with an isolated lingual metastasis 14 months after initial diagnosis.
  • The patient was a 71-year-old man with a history of pleural decortication and chemotherapy for epithelioid mesothelioma who recently complained of chronic bleeding from a nodular consolidation of tongue.
  • Microscopic examination of a lingual biopsy specimen revealed nests of atypical polygonal cells with moderate cytoplasm, immunopositive for keratins, epithelial membrane antigen, vimentin, thrombomodulin, and calretinin.
  • This case provides additional evidence that mesothelioma could rarely, but not exceptionally, metastatize, to unusual sites such as the tongue.
  • In addition to obvious medicolegal implication, metastatic mesothelioma should be correctly recognized so as to avoid useless radical treatment.
  • [MeSH-major] Mesothelioma / secondary. Pleural Neoplasms / secondary. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / chemistry. Epithelioid Cells / chemistry. Epithelioid Cells / pathology. Fatal Outcome. Humans. Immunohistochemistry. Male. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12598922.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


18. Shukunami K, Hirabuki S, Kaneshima M, Kamitani N, Kotsuji F: Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin. Tumori; 2000 Sep-Oct;86(5):419-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin.
  • Well-differentiated papillary mesothelioma (WDPM) of the peritoneum is a rare form of epithelial mesothelioma.
  • It usually shows an indolent course and no standard treatment is available.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ascites / etiology. Carboplatin / administration & dosage. Mesothelioma / diagnosis. Mesothelioma / drug therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / drug therapy. Pleural Effusion, Malignant / etiology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Cancer, Regional Perfusion. Diagnosis, Differential. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Instillation, Drug. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11130573.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


19. Sun X, Gulyás M, Hjerpe A, Dobra K: Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett; 2006 Feb 8;232(2):161-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells.
  • Malignant mesothelioma is an increasingly common tumor with an almost 100% mortality rate.
  • It is refractory to conventional treatment.
  • We have previously shown with SSH and microarray that the mRNA expression level of proteasome is higher in epithelioid mesothelioma cell lines than in sarcomatoid ones.
  • This study evaluates the differential apoptotic effect of proteasome inhibitors on both of these mesothelioma sub-lines.
  • Proteasome inhibitors show substantial anti-tumor activity in some tumor cells in vitro and in vivo, but the effects on mesothelioma cells has not been studied.
  • The viability of mesothelioma cells was reduced in a dose- and time-dependent manner by the proteasome inhibitors tested; PSI was effective with a low dose, but higher concentrations were needed for calpain inhibitor I.
  • The epithelioid mesothelioma cells are more sensitive to the inhibitors than the sarcomatoid ones, their IC50 after 24 h of treatment with PSI being 4 and 16 microm, respectively.
  • Other mesothelioma cell lines show similar sensitivity.
  • PSI seemed to decrease mesothelioma viability by inducing apoptosis, as verified by cell morphology, Western blotting analysis of caspase 3 cleavage, and flow-cytometric analysis.
  • In conclusion, PSI, a representative agent that reduces viability and induces apoptosis of mesothelioma cells, might be useful in the treatment of patients with mesothelioma, especially of epithelioid phenotype.
  • [MeSH-major] Apoptosis / drug effects. Cysteine Proteinase Inhibitors / pharmacology. Mesothelioma / drug therapy. Oligopeptides / pharmacology. Proteasome Inhibitors
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458112.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cysteine Proteinase Inhibitors; 0 / Oligopeptides; 0 / Proteasome Inhibitors; 0 / benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal
  •  go-up   go-down






Advertisement